|
|
Volumn 9, Issue 6, 2008, Pages 504-505
|
|
How not to treat cancer
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANTINEOPLASTIC AGENT;
CETUXIMAB;
CISPLATIN;
CYCLOPHOSPHAMIDE;
DOXORUBICIN;
EPIDERMAL GROWTH FACTOR RECEPTOR;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR;
ESTROGEN RECEPTOR;
EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1;
K RAS PROTEIN;
METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE;
PACLITAXEL;
PANITUMUMAB;
RAS PROTEIN;
TEMOZOLOMIDE;
BREAST TUMOR;
CANCER ADJUVANT THERAPY;
CANCER HORMONE THERAPY;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER RESISTANCE;
CANCER SURVIVAL;
CANCER THERAPY;
CLINICAL TRIAL;
COLORECTAL CANCER;
COST CONTROL;
DISEASE MARKER;
DNA METHYLATION;
DRUG COST;
DRUG USE;
GENE MUTATION;
GENOTYPE;
GLIOBLASTOMA;
HEALTH CARE COST;
HEALTH CARE SYSTEM;
HUMAN;
LETTER;
LUNG NON SMALL CELL CANCER;
LUNG RESECTION;
NEOPLASM;
PATIENT SELECTION;
PREDICTION;
PRIORITY JOURNAL;
PROGNOSIS;
PROMOTER REGION;
PROTEIN EXPRESSION;
RECURRENCE RISK;
TREATMENT INDICATION;
UNSPECIFIED SIDE EFFECT;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL MARKERS;
GENE EXPRESSION PROFILING;
GENE EXPRESSION REGULATION, NEOPLASTIC;
HUMANS;
NEOPLASMS;
PATIENT SELECTION;
PHARMACOGENETICS;
PREDICTIVE VALUE OF TESTS;
|
|
EID: 44249086881
PISSN: 14702045
EISSN: None
Source Type: Journal
DOI: 10.1016/S1470-2045(08)70134-7 Document Type: Letter |
|
Times cited : (2)
|
|
References (5)
|
